4-(4-cyanobenzenesulfonyl)piperazine-1-carboxylic acid tert-butyl ester | 913518-73-7

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: 4-(4-cyanobenzenesulfonyl)piperazine-1-carboxylic acid tert-butyl ester
• 英文别名: tert-butyl 4-((4-cyanophenyl)sulfonyl)piperazine-1-carboxylate；Tert-butyl 4-(4-cyanobenzenesulfonyl)piperazine-1-carboxylate；tert-butyl 4-(4-cyanophenyl)sulfonylpiperazine-1-carboxylate
• CAS: 913518-73-7
• 化学式: C₁₆H₂₁N₃O₄S
• 分子量: 351.426
• InChiKey: GXZNCYBWFGOLLP-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.4
• 重原子数：
  24
• 可旋转键数：
  4
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.5
• 拓扑面积：
  99.1
• 氢给体数：
  0
• 氢受体数：
  6

反应信息

• 作为反应物：
  描述：

  4-(4-cyanobenzenesulfonyl)piperazine-1-carboxylic acid tert-butyl ester 在 titanium(IV) isopropylate 、 sodium cyanoborohydride 、 三氟乙酸 作用下， 以 乙醇 、 二氯甲烷 为溶剂， 反应 19.0h， 生成 4-((4-(oxetan-3-yl)piperazin-1-yl)sulfonyl)benzonitrile
  参考文献：
  名称：

  Fragment-Based Identification of Amides Derived from trans-2-(Pyridin-3-yl)cyclopropanecarboxylic Acid as Potent Inhibitors of Human Nicotinamide Phosphoribosyltransferase (NAMPT)

  摘要：

  Potent, trans-2-(pyridin-3-yl)cyclopropane-carboxamide-containing inhibitors of the human nicotinamide phosphoribosyltransferase (NAMPT) enzyme were identified using fragment-based screening and structure-based design techniques. Multiple crystal structures were obtained of initial fragment leads, and this structural information was utilized to improve the biochemical and cell-based potency of the associated molecules. Many of the optimized compounds exhibited nanomolar antiproliferative activities against human tumor lines in in vitro cell culture experiments. In a key example, a fragment lead (13, K-D = 51 mu M) was elaborated into a potent NAMPT inhibitor (39, NAMPT IC50 = 0.0051 mu M, A2780 cell culture IC50 = 0.000 49 mu M) which demonstrated encouraging in vivo efficacy in an HT-1080 mouse xenograft tumor model.

  DOI：

  10.1021/jm4015108
• 作为产物：
  描述：

  4-氰基苯磺酰氯 、 N-Boc-哌嗪 在 N,N-二异丙基乙胺 作用下， 以 二氯甲烷 为溶剂， 反应 12.0h， 以77%的产率得到4-(4-cyanobenzenesulfonyl)piperazine-1-carboxylic acid tert-butyl ester
  参考文献：
  名称：

  [EN] AMIDO-BENZYL SULFONE AND SULFOXIDE DERIVATIVES
  [FR] DÉRIVÉS SULFOXYDES ET SULFONES AMIDO-BENZYLIQUES

  摘要：

  这项发明涉及某些酰胺基苯甲基亚砜和砜化合物，包括这些化合物的药物组合物，以及使用这些化合物进行治疗的方法。

  公开号：

  WO2013127266A1

文献信息

• 3-ARYL-5-SUBSTITUTED-ISOQUINOLIN-1-ONE COMPOUNDS AND THEIR THERAPEUTIC USE
  申请人：INSTITUTE OF CANCER RESEARCH: ROYAL CANCER HOSPITAL (THE)

  公开号：US20150099732A1

  公开（公告）日：2015-04-09

  The present invention pertains generally to the field of therapeutic compounds. More specifically the present invention pertains to certain 3-aryl-5-substituted-2H-isoquinolin-1-one compounds that, inter alia, inhibit PARP (e.g., PARP1, TNKS1, TNKS2, etc.) and/or Wnt signalling. The present invention also pertains to pharmaceutical compositions comprising such compounds, and the use of such compounds and compositions, both in vitro and in vivo, to inhibit PARP (e.g., PARP1, TNKS1, TNKS2, etc.); to inhibit Wnt signalling; to treat disorders that are ameliorated by the inhibition of PARP (e.g., PARP1, TNKS1, TNKS2, etc.); to treat disorders that are ameliorated by the inhibition of Wnt signalling; to treat proliferative conditions such as cancer, etc.

  本发明通常涉及治疗化合物领域。更具体地，本发明涉及某些3-芳基-5-取代-2H-异喹啉-1-酮化合物，该化合物在抑制PARP（例如PARP1，TNKS1，TNKS2等）和/或Wnt信号传导方面具有作用。本发明还涉及包含这些化合物的药物组合物，以及利用这些化合物和组合物，在体内和体外，来抑制PARP（例如PARP1，TNKS1，TNKS2等）；抑制Wnt信号传导；治疗通过抑制PARP（例如PARP1，TNKS1，TNKS2等）改善的疾病；治疗通过抑制Wnt信号传导改善的疾病；治疗癌症等增生症状。
• AMIDO-BENZYL SULFONE AND SULFOXIDE DERIVATIVES
  申请人：Bair Kenneth W.

  公开号：US20150104384A1

  公开（公告）日：2015-04-16

  The present invention relates to certain amido-benzyl sulfoxide and sulfone compounds, pharmaceutical compositions comprising such compounds, and methods of treatment using such compounds.

  本发明涉及某些酰胺基苯基亚砜和砜化合物，包括这些化合物的药物组合物和使用这些化合物的治疗方法。
• Amido-benzyl sulfone and sulfoxide derivates
  申请人：Forma TM, LLC

  公开号：US10696692B2

  公开（公告）日：2020-06-30

  The present invention relates to certain amido-benzyl sulfoxide and sulfone compounds, pharmaceutical compositions comprising such compounds, and methods of treatment using such compounds.

  本发明涉及某些氨基苄基亚砜和砜化合物、包含此类化合物的药物组合物以及使用此类化合物进行治疗的方法。
• 10.1016/j.bioorg.2024.107762
  作者：Ma, Bingjing、Li, Hua、Huang, Yuan、Guo, Yaming、Xu, Caizhu、Li, Wei

  DOI：10.1016/j.bioorg.2024.107762

  日期：——

  immune responses, which indicate that specific inhibition of JAK-STAT pathway would be a potential key strategy for RA (Rheumatoid arthritis) treatment. Cedrol (CE), found from ginger by our group earlier, has been proven to play an excellent role in ameliorating RA via acting on JAK3. In this study, 27 new (, –), along with one known () derivatives of CE were synthesized by using chloroacetic acid and

  JAK-STAT信号通路被认为在炎症性疾病和免疫反应的调节中发挥重要作用，这表明特异性抑制JAK-STAT通路将成为RA（类风湿性关节炎）治疗的潜在关键策略。本课题组前期从生姜中发现的雪松醇（CE）已被证明通过作用于JAK3对改善RA具有良好的作用。在这项研究中，使用氯乙酸和丙烯酰氯作为中间配体合成了 27 种新的 (, –) 以及一种已知的 () CE 衍生物。采用HTRF（均质时间分辨荧光）检测技术进行对JAK激酶的抑制效果，比传统方法更加方便、稳定。该结果与LPS诱导的p-JAK3的分泌相比，更能反映化合物真正的激酶选择性作用。该化合物被确定为一种有效的抑制剂，可以以剂量依赖性方式减少 LPS 诱导的 p-JAK3 的分泌。鉴于这些结果，该化合物可以作为 JAK3 的有利抑制剂进行进一步研究。
• Evaluation of Substituted <i>N</i>,<i>N</i>′-Diarylsulfonamides as Activators of the Tumor Cell Specific M2 Isoform of Pyruvate Kinase
  作者：Matthew B. Boxer、Jian-kang Jiang、Matthew G. Vander Heiden、Min Shen、Amanda P. Skoumbourdis、Noel Southall、Henrike Veith、William Leister、Christopher P. Austin、Hee Won Park、James Inglese、Lewis C. Cantley、Douglas S. Auld、Craig J. Thomas

  DOI：10.1021/jm901577g

  日期：2010.2.11

  The metabolism of cancer cells is altered to support rapid proliferation. Pharmacological activators of a tumor cell specific pyruvate kinase isozyme (PKM2) may be an approach for altering the classic Warburg effect characteristic of aberrant metabolism in cancer cells yielding a novel anti proliferation strategy. In this manuscript, we detail the discovery of a series of Substituted N,N'-diarylsulfonamides as activators of PKM2. The synthesis of numerous analogues and the evaluation of structure-activity relationships are presented as well as assessments of mechanism and selectivity. Several agents are found that have good potencies and appropriate solubility for use as chemical probes of PKM2 including 55 (AC(50) = 43 nM, maximum response = 84%; solubility = 7.3 mu g/mL), 56 (AC(50) = 99 nM, maximum response 84%; solubility = 5.7 mu g/mL), and 58 (AC(50) = 38 nM, maximum response = 82%; solubility 51.2 mu g/mL). The small molecules described here represent first-in-class activators of PKM2